GlycoMimetics (GLYC) Tops Q1 EPS by 12c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
GlycoMimetics Reports Operational Highlights and Financial Results for First Quarter 2020
May 1, 2020 7:00 AM EDTEntered into an exclusive collaboration and license agreement with Apollomics for development and commercialization of uproleselan and GMI-1687 in the Greater China region Announced first patient dosing in Phase 1b clinical trial of GMI-1359 in individuals with advanced breast cancer, led by co-principal investigators from the Duke Cancer Institute Reiterated a commitment to determine what, if any, next steps to take with respect to the rivipansel program following transfer from Pfizer of the IND and the full Phase 3 RESET dataset To host conference call and webcast today at... More
